Skip to main content

Stephanie Gaillard

Adjunct Assistant Professor in the Department of Medicine
Medicine, Medical Oncology
DUMC 3079, Durham, NC 27710
DUMC Box 3079, Durham, NC 27710

Overview


Dr. Stéphanie Gaillard is an Assistant Professor in Medical Oncology at the Duke Cancer Institute. Dr. Gaillard is board certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. At Duke, she focuses on treating patients with gynecologic malignancies and conducts basic science and clinical research. Dr. Gaillard’s laboratory research focuses on elucidating the biology of ovarian cancer, especially metabolic changes in the development of ovarian tumors, and mechanisms of resistance to chemotherapy. Her clinical research interests center on the development of novel therapeutic strategies for the treatment of ovarian cancer through early phase clinical trials. In addition to the Ovarian Cancer Research Fund Liz Tilberis Grant, Dr. Gaillard has received a Department of Defense Breast Cancer Research Program pre-doctoral research award and a Conquer Cancer Foundation Young Investigator Award.

Current Duke Appointments & Affiliations


Adjunct Assistant Professor in the Department of Medicine · 2017 - Present Medicine, Medical Oncology, Medicine

Recent Scholarly Works


Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Journal article Gynecol Oncol · June 12, 2026 OBJECTIVE: Evaluate safety, efficacy, and response markers to atezolizumab, an immune checkpoint inhibitor, when combined with neoadjuvant chemotherapy (NACT) for primary epithelial ovarian, tubal, and peritoneal cancer (EOC). METHODS: Eligible patients ha ... Full text Link to item Cite

Puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4–selected advanced/metastatic endometrial cancer: The phase 3 randomized Bluestar-Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial.

Journal article Journal of Clinical Oncology · June 1, 2026 TPS5647Background: The transmembrane glycoprotein B7-H4 is highly expressed in endometrial cancer (EC), with limited expression in normal tissue; therefore, B7-H4 is an attractive antibody–drug conjugate (ADC) target in the treatment of advanced/recurrent ... Full text Cite

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal article J Natl Compr Canc Netw · March 2026 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vaginal Cancer outline the recommended diagnostic workup, staging considerations, and treatment options for this rare malignancy. Because vaginal cancer is uncommon and shares many bio ... Full text Link to item Cite
View All Scholarly Works